28 related articles for article (PubMed ID: 7780483)
1. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract][Full Text] [Related]
2. Activity of a short course of interferon alpha for metastatic renal cell carcinoma--a phase-2 study.
Abratt RP; Pontin AR; Ball HS
Cancer Immunol Immunother; 1993 Jul; 37(2):140-1. PubMed ID: 8319243
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Waters JS; Moss C; Pyle L; James M; Hackett S; A'hern R; Gore M; Eisen T
Br J Cancer; 2004 Nov; 91(10):1763-8. PubMed ID: 15505625
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
Göhring B; Riemann D; Rebmann U; Heynemann H; Schabel J; Langner J
Urol Res; 1996; 24(5):297-303. PubMed ID: 8931295
[TBL] [Abstract][Full Text] [Related]
5. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
8. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.
Lopez Hanninen E; Poliwoda H; Atzpodien J
Cancer Biother; 1995; 10(1):21-4. PubMed ID: 7780483
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
11. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
